Thalidomide-NH-C6-NH2 hydrochloride is primarily utilized in research and development within the pharmaceutical industry, particularly in the study of immunomodulatory and anti-inflammatory agents. It is often explored for its potential in targeting specific biological pathways, such as those involved in cancer therapy and autoimmune diseases. The compound is also investigated for its ability to inhibit angiogenesis, making it a candidate for treating conditions like multiple myeloma and other malignancies. Additionally, it is used in experimental studies to understand its interactions with cellular receptors and its impact on cytokine production. Researchers focus on optimizing its structure to enhance efficacy and reduce side effects, aiming to develop safer and more effective therapeutic options.